JP2023550094A5 - - Google Patents
Info
- Publication number
- JP2023550094A5 JP2023550094A5 JP2023529970A JP2023529970A JP2023550094A5 JP 2023550094 A5 JP2023550094 A5 JP 2023550094A5 JP 2023529970 A JP2023529970 A JP 2023529970A JP 2023529970 A JP2023529970 A JP 2023529970A JP 2023550094 A5 JP2023550094 A5 JP 2023550094A5
- Authority
- JP
- Japan
- Prior art keywords
- hla
- peptide
- optionally
- mhc
- cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063113024P | 2020-11-12 | 2020-11-12 | |
| US63/113,024 | 2020-11-12 | ||
| PCT/US2021/059050 WO2022104002A2 (en) | 2020-11-12 | 2021-11-12 | Sars-cov-2 immunodominant peptide constructs and uses thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023550094A JP2023550094A (ja) | 2023-11-30 |
| JP2023550094A5 true JP2023550094A5 (cg-RX-API-DMAC7.html) | 2025-07-22 |
| JP7895943B2 JP7895943B2 (ja) | 2026-07-28 |
Family
ID=81601698
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023529970A Active JP7895943B2 (ja) | 2020-11-12 | 2021-11-12 | Sars-cov-2免疫優性ペプチドの構築物及びその使用 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20230398205A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4244630A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP7895943B2 (cg-RX-API-DMAC7.html) |
| AR (1) | AR124054A1 (cg-RX-API-DMAC7.html) |
| AU (3) | AU2021323389B1 (cg-RX-API-DMAC7.html) |
| TW (1) | TW202237626A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2022104002A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115785231A (zh) * | 2021-09-10 | 2023-03-14 | 广东菲鹏生物有限公司 | 一种鉴别新冠突变型抗原的抗体、试剂及方法 |
| CN120302989A (zh) * | 2022-10-05 | 2025-07-11 | 帝斯肯医疗公司 | Magea1免疫原性肽、识别magea1免疫原性肽的结合蛋白和其用途 |
| AU2023241306B2 (en) * | 2022-10-05 | 2024-10-03 | Tscan Therapeutics, Inc. | Prame immunogenic peptides, binding proteins recognizing prame immunogenic peptides, and uses thereof |
| WO2025202937A1 (en) | 2024-03-26 | 2025-10-02 | BioNTech SE | Cancer vaccines |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1571909A4 (en) * | 2002-10-03 | 2009-11-11 | Idm Pharma Inc | OPTIMIZED MULTIPOPOP CONSTRUCTS AND USES THEREOF |
| US20060257852A1 (en) * | 2003-04-10 | 2006-11-16 | Chiron Corporation | Severe acute respiratory syndrome coronavirus |
| CA2523875A1 (en) * | 2003-04-28 | 2004-11-11 | Public Health Agency Of Canada | Sars virus nucleotide and amino acid sequences and uses thereof |
| WO2004110349A2 (en) * | 2003-05-14 | 2004-12-23 | Siga Technologies, Inc. | Sars t cell epitopes and methods for identifying same |
| US11608363B2 (en) * | 2018-07-03 | 2023-03-21 | Leidos, Inc | Materials and methods for cell-free expression of vaccine epitope concatemers |
| BR112021023348A2 (pt) * | 2019-05-21 | 2022-02-01 | Esperovax Inc | Vacinação oral à base de levedura |
| CA3143533A1 (en) * | 2019-08-01 | 2021-02-04 | Madhavan Nallani | A method of eliciting an immune response by administering a population of polymersomes having an associated antigen together with a population of polymersomes having an associated adjuvant as well as compositions comprising the two populations of polymersome |
| HUE058338T2 (hu) * | 2020-02-20 | 2022-07-28 | Euroimmun Medizinische Labordiagnostika Ag | Eljárás és reagensek SARS-COV-2 diagnózisára |
| TW202200199A (zh) * | 2020-03-20 | 2022-01-01 | 美商百歐恩泰美國公司 | 冠狀病毒疫苗及使用方法 |
| IT202000006754A1 (it) * | 2020-03-31 | 2021-10-01 | Diasorin S P A | Saggi per la rivelazione di SARS-CoV-2 |
| CR20220552A (es) * | 2020-04-02 | 2023-01-17 | Regeneron Pharma | Anticuerpos contra glicoproteína de espícula anti-sars-cov-2 y fragmentos de unión al antígeno |
| CN118490818A (zh) * | 2020-04-22 | 2024-08-16 | 生物技术欧洲股份公司 | 冠状病毒疫苗 |
| MX2022013945A (es) * | 2020-05-06 | 2023-02-14 | Molecular Partners Ag | Nuevas proteinas de union a repeticiones de anquirina y sus usos. |
| CA3178115A1 (en) * | 2020-05-19 | 2021-11-25 | Roman YELENSKY | Sars-cov-2 vaccines |
| CN111647054B (zh) * | 2020-06-12 | 2021-12-03 | 上海祥耀生物科技有限责任公司 | 一种用于检测新型冠状病毒SARS-CoV-2抗体的试剂及其应用 |
| CA3187028A1 (en) * | 2020-06-17 | 2021-12-23 | Tscan Therapeutics, Inc. | Sars-cov-2 immunodominant peptides and uses thereof |
| EP4208193A4 (en) * | 2020-09-01 | 2024-09-25 | Helmholtz-Zentrum für Infektionsforschung GmbH | MULTI-REGION VACCINES AND IMMUNOGENIC COMPOSITIONS, THEIR PRODUCTION METHODS AND THEIR USES |
-
2021
- 2021-11-12 JP JP2023529970A patent/JP7895943B2/ja active Active
- 2021-11-12 AR ARP210103138A patent/AR124054A1/es unknown
- 2021-11-12 EP EP21892837.2A patent/EP4244630A4/en active Pending
- 2021-11-12 AU AU2021323389A patent/AU2021323389B1/en active Active
- 2021-11-12 TW TW110142318A patent/TW202237626A/zh unknown
- 2021-11-12 US US18/035,369 patent/US20230398205A1/en active Pending
- 2021-11-12 WO PCT/US2021/059050 patent/WO2022104002A2/en not_active Ceased
-
2022
- 2022-06-21 AU AU2022204350A patent/AU2022204350B2/en active Active
-
2024
- 2024-08-14 AU AU2024205749A patent/AU2024205749A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20210017599A1 (en) | Cancer antigen-specific t-cell receptor gene, peptide encoded by the gene, and use of them | |
| JP6192537B2 (ja) | T細胞の標的抗原の同定 | |
| Romero et al. | Novel methods to monitor antigen-specific cytotoxic T-cell responses in cancer immunotherapy | |
| US20050130117A1 (en) | Modulators of lymphocyte activation and migration | |
| JP6718450B2 (ja) | キメラ抗原受容体及びその使用方法 | |
| US7678379B2 (en) | Mycobacterium tuberculosis epitopes and methods of use thereof | |
| CN114019156A (zh) | 免疫突触的质量预测了嵌合抗原受体(car)t细胞的效能 | |
| JP2024546018A5 (cg-RX-API-DMAC7.html) | ||
| JP2007536522A (ja) | Ctlの媒介による抗原提示細胞の溶解を検出するためのmhc架橋系 | |
| US7521192B2 (en) | EDG: modulators of lymphocyte activation and migration | |
| Hill et al. | Early‐onset myasthenia gravis: A recurring T‐cell epitope in the adult‐specific acetylcholine receptor ε subunit presented by the susceptibility allele HLA‐DR52a | |
| AR124054A1 (es) | CONSTRUCCIONES DE PÉPTIDOS INMUNODOMINANTES DE SARS-CoV-2 Y SUS USOS | |
| JP2024515646A5 (cg-RX-API-DMAC7.html) | ||
| JP5999703B2 (ja) | HLA−DR1拘束性Tax特異的CD4+T細胞エピトープ | |
| EP4378533A1 (en) | Patient selection and therapy monitoring for autoimmune disorders | |
| Asano et al. | Tumor regression following engineered polyomavirus-specific T cell therapy in immune checkpoint inhibitor-refractory merkel cell carcinoma | |
| US20130189282A1 (en) | Methods for isolating and using a subset of cd8 t-cells that are resistant to cyclosporin | |
| ES3041245T3 (en) | Methods for detecting a mycobacterium tuberculosis infection | |
| Levin et al. | Availability of autoantigenic epitopes controls phenotype, severity, and penetrance in TCR Tg autoimmune gastritis | |
| US20030013107A1 (en) | Alpha 2 integrin: modulators of lymphocyte activation | |
| IL310374A (en) | Antigen binding proteins that uniquely bind CT45 | |
| WO2011040978A2 (en) | Immunodominant mhc dr52b restricted ny-eso-1 epitopes, mhc class ii monomers and multimers, and uses thereof | |
| US20020146747A1 (en) | TRAC1: modulators of lymphocyte activation | |
| EISEN et al. | VIII. Altered Peptide Ligands: Partial Agonists and Antagonists............... 4 1 IX. MHC Restriction by Self and Nonself MHC: The Paradox of Alloaggression. 43 | |
| US20050250113A1 (en) | Mammalian magnesium/manganese sensing G protein coupled receptor |